AHCO Quote, Financials, Valuation and Earnings

Electromed has a net margin of 3.41% compared to AdaptHealth's net margin of 12.11%. AdaptHealth's return on equity of 6% beat Electromed's return on equity of 15.91%.

AdaptHealth has a consensus price target of $13.00, signalling upside risk potential of 50.12%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 64.23%. Given that Electromed has higher upside potential than AdaptHealth, analysts believe Electromed is more attractive than AdaptHealth.

AdaptHealth has a beta of 1.444, which suggesting that the stock is 44.377% more volatile than S&P 500. In comparison Electromed has a beta of 0.594, suggesting its less volatile than the S&P 500 by 40.575%.

AdaptHealth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AdaptHealth pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

AdaptHealth quarterly revenues are $1.5B, which are larger than Electromed quarterly revenues of $16.3M. AdaptHealth's net income of $50.3M is higher than Electromed's net income of $2M. Notably, AdaptHealth's price-to-earnings ratio is 14.43x while Electromed's PE ratio is 30.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AdaptHealth is 0.36x versus 3.38x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

IRIDEX has a net margin of 3.41% compared to AdaptHealth's net margin of -16.69%. AdaptHealth's return on equity of 6% beat IRIDEX's return on equity of -157.91%.

AdaptHealth has a consensus price target of $13.00, signalling upside risk potential of 50.12%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 112.2%. Given that IRIDEX has higher upside potential than AdaptHealth, analysts believe IRIDEX is more attractive than AdaptHealth.

AdaptHealth has a beta of 1.444, which suggesting that the stock is 44.377% more volatile than S&P 500. In comparison IRIDEX has a beta of 0.737, suggesting its less volatile than the S&P 500 by 26.316%.

AdaptHealth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AdaptHealth pays -- of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend.

AdaptHealth quarterly revenues are $1.5B, which are larger than IRIDEX quarterly revenues of $11.6M. AdaptHealth's net income of $50.3M is higher than IRIDEX's net income of -$1.9M. Notably, AdaptHealth's price-to-earnings ratio is 14.43x while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AdaptHealth is 0.36x versus 0.32x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of 3.41% compared to AdaptHealth's net margin of -2.16%. AdaptHealth's return on equity of 6% beat Myomo's return on equity of -48.64%.

AdaptHealth has a consensus price target of $13.00, signalling upside risk potential of 50.12%. On the other hand Myomo has an analysts' consensus of $9.25 which suggests that it could grow by 108.8%. Given that Myomo has higher upside potential than AdaptHealth, analysts believe Myomo is more attractive than AdaptHealth.

AdaptHealth has a beta of 1.444, which suggesting that the stock is 44.377% more volatile than S&P 500. In comparison Myomo has a beta of 1.548, suggesting its more volatile than the S&P 500 by 54.752%.

AdaptHealth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AdaptHealth pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

AdaptHealth quarterly revenues are $1.5B, which are larger than Myomo quarterly revenues of $12.1M. AdaptHealth's net income of $50.3M is higher than Myomo's net income of -$260.1K. Notably, AdaptHealth's price-to-earnings ratio is 14.43x while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AdaptHealth is 0.36x versus 5.14x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of 3.41% compared to AdaptHealth's net margin of -118.53%. AdaptHealth's return on equity of 6% beat Stereotaxis's return on equity of -139.2%.

AdaptHealth has a consensus price target of $13.00, signalling upside risk potential of 50.12%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 171.08%. Given that Stereotaxis has higher upside potential than AdaptHealth, analysts believe Stereotaxis is more attractive than AdaptHealth.

AdaptHealth has a beta of 1.444, which suggesting that the stock is 44.377% more volatile than S&P 500. In comparison Stereotaxis has a beta of 1.602, suggesting its more volatile than the S&P 500 by 60.223%.

AdaptHealth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AdaptHealth pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

AdaptHealth quarterly revenues are $1.5B, which are larger than Stereotaxis quarterly revenues of $6.3M. AdaptHealth's net income of $50.3M is higher than Stereotaxis's net income of -$7.5M. Notably, AdaptHealth's price-to-earnings ratio is 14.43x while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AdaptHealth is 0.36x versus 5.25x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.